Leap Therapeutics Files 8-K on Financials

Ticker: CYPH · Form: 8-K · Filed: May 13, 2025 · CIK: 1509745

Leap Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyLeap Therapeutics, INC. (CYPH)
Form Type8-K
Filed DateMay 13, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Leap Therapeutics dropped an 8-K on financials, check it out.

AI Summary

Leap Therapeutics, Inc. filed an 8-K on May 13, 2025, reporting on its Results of Operations and Financial Condition, and filing Financial Statements and Exhibits. The company, incorporated in Delaware, is based in Cambridge, MA.

Why It Matters

This filing provides investors with an update on Leap Therapeutics' financial performance and condition, which is crucial for evaluating the company's stability and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What specific financial statements or exhibits were filed with this 8-K?

The filing indicates that 'Financial Statements and Exhibits' were included, but the specific details of these documents are not provided in the summary text.

What is the IRS Employer Identification Number for Leap Therapeutics, Inc.?

The IRS Employer Identification Number for Leap Therapeutics, Inc. is 27-4412575.

When did Leap Therapeutics, Inc. change its name from Dekkun Corp?

The date of the name change from Dekkun Corp was January 7, 2011.

What is the Standard Industrial Classification code for Leap Therapeutics, Inc.?

The Standard Industrial Classification code for Leap Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the telephone number for Leap Therapeutics, Inc.?

The telephone number for Leap Therapeutics, Inc., including the area code, is (617) 714-0360.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding LEAP THERAPEUTICS, INC. (CYPH).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing